Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IQ0Z
|
|||
| Former ID |
DCL001072
|
|||
| Drug Name |
GSK1070916
|
|||
| Synonyms |
GSK-1070916
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Advanced solid tumour [ICD-11: 2A00-2F9Z; ICD-9: 140-199] | Phase 1 | [1], [2] | |
| Company |
GlaxoSmith-Kline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H33N7O
|
|||
| Canonical SMILES |
CCN1C=C(C(=N1)C2=CC=C(C=C2)NC(=O)N(C)C)C3=C4C=C(NC4=NC=C3)C5=CC=CC(=C5)CN(C)C
|
|||
| InChI |
1S/C30H33N7O/c1-6-37-19-26(28(34-37)21-10-12-23(13-11-21)32-30(38)36(4)5)24-14-15-31-29-25(24)17-27(33-29)22-9-7-8-20(16-22)18-35(2)3/h7-17,19H,6,18H2,1-5H3,(H,31,33)(H,32,38)
|
|||
| InChIKey |
QTBWCSQGBMPECM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 942918-07-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
103748127, 104150130, 109692758, 120907915, 125748893, 134339469, 134347882, 135315559, 135686172, 135686173, 135686194, 135686195, 136348839, 136349579, 136367710, 137130830, 139905068, 144116024, 152258884, 152344275, 160647733, 162011765, 162038111, 164194002, 165238064, 165246679, 174006386, 174531617, 177748955, 180371646, 198945210, 203088743, 223258873, 223685850, 224105858, 230247385, 242979888, 251963082, 251971181, 252166570, 252215499, 252359510, 252451734
|
|||
| ChEBI ID |
CHEBI:91362
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aurora kinase B (AURKB) | Target Info | Modulator | [3] |
| Aurora kinase C (AURKC) | Target Info | Modulator | [3] | |
| KEGG Pathway | Oocyte meiosis | |||
| Pathway Interaction Database | Aurora B signaling | |||
| Signaling by Aurora kinases | ||||
| Aurora C signaling | ||||
| FOXM1 transcription factor network | ||||
| Aurora A signaling | ||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||
| Separation of Sister Chromatids | ||||
| Resolution of Sister Chromatid Cohesion | ||||
| RHO GTPases Activate Formins | ||||
| Mitotic Prometaphase | ||||
| WikiPathways | Mitotic Metaphase and Anaphase | |||
| Mitotic Prometaphase | ||||
| Regulation of Microtubule Cytoskeleton | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| APC/C-mediated degradation of cell cycle proteins | ||||
| EGF/EGFR Signaling Pathway | ||||
| JAK/STAT | ||||
| Gastric Cancer Network 1 | ||||
| Integrated Breast Cancer Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8358). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032133) | |||
| REF 3 | Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.